Loading
A phase 3 trial of Zanubrutinib, Bendamustine, Rituximab in hodgkin lymphoma and mantle cell lymphoma, run by BeOne Medicines, active and no longer recruiting.
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation is a phase 3 interventional study registered as NCT04002297 by BeOne Medicines, with 510 participants enrolled, started 2019-08-20 and due to reach its primary completion in 2027-03. Interventions recorded: zanubrutinib, bendamustine, rituximab. Conditions listed: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Shares Bendamustine, Rituximab, Mantle cell lymphoma, Monoclonal antibodies.
Shares Bendamustine, BeOne Medicines (formerly BeiGene), Rituximab, Monoclonal antibodies.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Small-molecule kinase inhibitors.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Small-molecule kinase inhibitors.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Rituximab, Monoclonal antibodies.
Shares Bendamustine, Rituximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Non-Hodgkin lymphoma (all types), Small-molecule kinase inhibitors.
Shares Bendamustine, Rituximab, Monoclonal antibodies, Small-molecule kinase inhibitors.